Abstract: Disclosed are methods of, and assay and kits for, detecting and diagnosing arterial plaque rupture using the expression of miR-222, mi-221 and circ284. Also disclosed are methods of treating arterial plaque rupture and methods of identifying agents for use thin the treatment of arterial plaque rupture.

Abstract: A method for use in determining a position of a mobile device in a wireless communication network includes acquiring, by the mobile device, a first positioning signal transmitted at a first frequency and a second positioning signal transmitted at a second frequency that is different than the first frequency. The mobile device performs a first measurement of a time difference of arrival between the first positioning signal and second positioning signal. In certain implementations, in response to a determination to not apply an inter-frequency bias compensation to the first measurement for inter-frequency related delays corresponding to first frequency, second frequency, or both first and second frequency, the mobile device sends the first measurement and a first measurement description to a server to determine the position of the mobile device. The first measurement description indicates that the first measurement has not been compensated for the inter-frequency related delays.

Abstract: The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5? adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.

Abstract: The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5? adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.

Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.

Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.